NCT00270894 - Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Breast Neoplasm

Interventions

DRUG

epirubicin

epirubicin (100 mg/m\^2) every 2 weeks for 4 cycles

DRUG

cyclophosphamide

cyclophosphamide (600 mg/m\^2) every 2 weeks for 4 cycles

DRUG

docetaxel

docetaxel (75 mg/m\^2) every 2 weeks for 4 cycles

DRUG

trastuzumab

trastuzumab (6 mg/kg \[loading dose\] once then 4 mg/kg \[maintenance dose\]) every 2 weeks for 4 treatments

Trial Locations (7)

Arena Oncology Associates, Great Neck

Northwest Georgia Oncology Centers, PC, Marietta

Augusta Oncology Associates, Augusta

Cental Georgia Cancer Care, Macon

Advanced Medical Specialties, Miami

The West Clinic, Memphis

Hematology Oncology Centers of the Northern Rockies, PC, Billings